BR112012021247A2 - solução oftálmica para tratar infecção ocular compreendendo levofloxacina ou sal ou solvato da mesma, método para tratar infecção ocular, levofloxacina ou sal ou solvato da mesma e uso da mesma. - Google Patents
solução oftálmica para tratar infecção ocular compreendendo levofloxacina ou sal ou solvato da mesma, método para tratar infecção ocular, levofloxacina ou sal ou solvato da mesma e uso da mesma.Info
- Publication number
- BR112012021247A2 BR112012021247A2 BR112012021247-8A BR112012021247A BR112012021247A2 BR 112012021247 A2 BR112012021247 A2 BR 112012021247A2 BR 112012021247 A BR112012021247 A BR 112012021247A BR 112012021247 A2 BR112012021247 A2 BR 112012021247A2
- Authority
- BR
- Brazil
- Prior art keywords
- levofloxacin
- ophthalmic solution
- solvate
- eye infection
- salt
- Prior art date
Links
- 208000001860 Eye Infections Diseases 0.000 title abstract 7
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 title abstract 7
- 229960003376 levofloxacin Drugs 0.000 title abstract 7
- 208000011323 eye infectious disease Diseases 0.000 title abstract 6
- 229940054534 ophthalmic solution Drugs 0.000 title abstract 4
- 239000002997 ophthalmic solution Substances 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 4
- 239000012453 solvate Substances 0.000 title abstract 4
- 229940114474 levofloxacin ophthalmic solution Drugs 0.000 abstract 4
- 241000894006 Bacteria Species 0.000 abstract 3
- 201000007032 bacterial conjunctivitis Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010040281 | 2010-02-25 | ||
| JP2010-040281 | 2010-02-25 | ||
| PCT/JP2010/072685 WO2011104981A1 (ja) | 2010-02-25 | 2010-12-16 | レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤、眼感染症の治療方法、レボフロキサシンもしくはその塩またはそれらの溶媒和物、ならびにその使用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012021247A2 true BR112012021247A2 (pt) | 2018-04-03 |
Family
ID=44506417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012021247-8A BR112012021247A2 (pt) | 2010-02-25 | 2010-12-16 | solução oftálmica para tratar infecção ocular compreendendo levofloxacina ou sal ou solvato da mesma, método para tratar infecção ocular, levofloxacina ou sal ou solvato da mesma e uso da mesma. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20120316158A1 (https=) |
| EP (1) | EP2540299B1 (https=) |
| JP (3) | JP5600056B2 (https=) |
| KR (2) | KR20130043611A (https=) |
| CN (1) | CN102770141A (https=) |
| BR (1) | BR112012021247A2 (https=) |
| CA (1) | CA2791190C (https=) |
| EA (1) | EA201290827A1 (https=) |
| ES (1) | ES2568647T3 (https=) |
| MX (1) | MX349603B (https=) |
| MY (1) | MY183483A (https=) |
| NZ (1) | NZ602126A (https=) |
| PH (2) | PH12016501747B1 (https=) |
| SG (1) | SG183427A1 (https=) |
| TW (1) | TWI488627B (https=) |
| WO (1) | WO2011104981A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12016501747B1 (en) * | 2010-02-25 | 2022-06-22 | Daiichi Sankyo Co Ltd | Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof |
| CN103550144B (zh) * | 2013-10-25 | 2015-10-14 | 深圳朗欧医药集团有限公司 | 盐酸左氧氟沙星组合物注射液及其制备方法 |
| JP6363833B2 (ja) * | 2013-11-22 | 2018-07-25 | ナノシータ株式会社 | 薄膜状高分子構造体 |
| CN104606198A (zh) * | 2015-01-09 | 2015-05-13 | 周元铎 | 盐酸左氧氟沙星在制备防治家蚕细菌性败血病药中的应用 |
| IT201900005280A1 (it) * | 2019-04-05 | 2020-10-05 | Ntc S R L | Composizione otologica |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3038722B2 (ja) | 1989-06-23 | 2000-05-08 | 日本電気株式会社 | 接合型電界効果トランジスタ |
| JP3192290B2 (ja) | 1993-08-04 | 2001-07-23 | カネボウ株式会社 | ポリエステル製耐熱ボトル |
| WO2003028664A2 (en) * | 2001-10-03 | 2003-04-10 | Teva Pharmaceutical Industries Ltd. | Preparation of levofloxacin and forms thereof |
| EP1458391B1 (en) * | 2001-11-30 | 2007-09-05 | LG Life Sciences Ltd. | A method of treating bacterial infections using gemifloxacin or a salt thereof and a beta-lactam antibiotic |
| US20050009836A1 (en) | 2003-06-26 | 2005-01-13 | Laskar Paul A. | Ophthalmic composition containing quinolones and method of use |
| WO2005000307A1 (en) * | 2003-06-26 | 2005-01-06 | Santen Pharmaceutical Co., Ltd. | Ophthalmic composition containing quinolones and method of use |
| ES2671342T3 (es) * | 2006-02-10 | 2018-06-06 | Pari Pharma Gmbh | Antibióticos nebulizados para terapia de inhalación |
| WO2008005276A2 (en) * | 2006-06-30 | 2008-01-10 | Directcontact Llc | Growth factor delivery system containing antimicrobial agents |
| EP2143422A1 (en) * | 2008-07-11 | 2010-01-13 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections |
| PH12016501747B1 (en) * | 2010-02-25 | 2022-06-22 | Daiichi Sankyo Co Ltd | Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof |
-
2010
- 2010-12-16 PH PH1/2016/501747A patent/PH12016501747B1/en unknown
- 2010-12-16 SG SG2012061842A patent/SG183427A1/en unknown
- 2010-12-16 MX MX2012009844A patent/MX349603B/es active IP Right Grant
- 2010-12-16 KR KR1020127024069A patent/KR20130043611A/ko not_active Ceased
- 2010-12-16 US US13/580,931 patent/US20120316158A1/en not_active Abandoned
- 2010-12-16 WO PCT/JP2010/072685 patent/WO2011104981A1/ja not_active Ceased
- 2010-12-16 NZ NZ602126A patent/NZ602126A/xx not_active IP Right Cessation
- 2010-12-16 BR BR112012021247-8A patent/BR112012021247A2/pt not_active Application Discontinuation
- 2010-12-16 PH PH1/2012/501674A patent/PH12012501674A1/en unknown
- 2010-12-16 MY MYPI2012003769A patent/MY183483A/en unknown
- 2010-12-16 EA EA201290827A patent/EA201290827A1/ru unknown
- 2010-12-16 ES ES10846644.2T patent/ES2568647T3/es active Active
- 2010-12-16 EP EP10846644.2A patent/EP2540299B1/en not_active Not-in-force
- 2010-12-16 CN CN2010800646540A patent/CN102770141A/zh active Pending
- 2010-12-16 JP JP2010280325A patent/JP5600056B2/ja active Active
- 2010-12-16 KR KR1020177015979A patent/KR20170070265A/ko not_active Ceased
- 2010-12-16 CA CA2791190A patent/CA2791190C/en not_active Expired - Fee Related
- 2010-12-28 TW TW099146206A patent/TWI488627B/zh not_active IP Right Cessation
-
2012
- 2012-03-12 JP JP2012054761A patent/JP2012162532A/ja active Pending
-
2013
- 2013-08-16 JP JP2013169146A patent/JP5674882B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG183427A1 (en) | 2012-09-27 |
| NZ602126A (en) | 2013-10-25 |
| WO2011104981A1 (ja) | 2011-09-01 |
| JP5600056B2 (ja) | 2014-10-01 |
| MX2012009844A (es) | 2012-09-21 |
| PH12016501747A1 (en) | 2019-02-11 |
| JP2013241464A (ja) | 2013-12-05 |
| KR20130043611A (ko) | 2013-04-30 |
| JP5674882B2 (ja) | 2015-02-25 |
| EA201290827A1 (ru) | 2013-03-29 |
| EP2540299A4 (en) | 2013-07-24 |
| CN102770141A (zh) | 2012-11-07 |
| AU2010346703A1 (en) | 2012-09-20 |
| ES2568647T3 (es) | 2016-05-03 |
| TWI488627B (zh) | 2015-06-21 |
| CA2791190C (en) | 2017-12-12 |
| KR20170070265A (ko) | 2017-06-21 |
| JP2011195564A (ja) | 2011-10-06 |
| PH12012501674A1 (en) | 2012-11-05 |
| PH12016501747B1 (en) | 2022-06-22 |
| US20120316158A1 (en) | 2012-12-13 |
| EP2540299A1 (en) | 2013-01-02 |
| EP2540299B1 (en) | 2016-04-13 |
| CA2791190A1 (en) | 2011-09-01 |
| MX349603B (es) | 2017-08-03 |
| MY183483A (en) | 2021-02-20 |
| TW201129364A (en) | 2011-09-01 |
| JP2012162532A (ja) | 2012-08-30 |
| HK1177887A1 (en) | 2013-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021009595A2 (pt) | Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres | |
| BR112015021334A2 (pt) | formulações oculares para entrega de droga ao segmento posterior do olho | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| BR112018008358A2 (pt) | ?composições e métodos para terapia relacionada à microbiota fecal? | |
| MX2017017171A (es) | Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. | |
| BR112018008965A8 (pt) | terapia de reposição de plasminogênio para deficiência de plasminogênio | |
| BR112013017875A2 (pt) | introdução corneana de agentes de ligação cruzada por iontoforese para o tratamento de ceratocone e composições oftálmicas relacionadas | |
| BR112012021247A2 (pt) | solução oftálmica para tratar infecção ocular compreendendo levofloxacina ou sal ou solvato da mesma, método para tratar infecção ocular, levofloxacina ou sal ou solvato da mesma e uso da mesma. | |
| MX2015009269A (es) | Composiciones farmaceuticas que comprenden donadores de nitroxilo. | |
| BR112018003232A2 (pt) | terapias de combinação para tratamento de câncer | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112019007763A2 (pt) | composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção | |
| MX389553B (es) | Composicion para incrementar la expresion de pgc-1alfa | |
| BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| BR112017013674A2 (pt) | métodos e composições para tratamento de doenças cerebrais. | |
| BR112021024716A2 (pt) | Ruptura de biofilme | |
| BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
| BRPI0916885B8 (pt) | composição farmacêutica | |
| GB2541840A (en) | Ophthalmic composition for the treatment of ocular infection | |
| BR112018070514A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| BR112019024082A2 (pt) | Métodos de tratamento para distonia cervical | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| MX2022006229A (es) | Composiciones y metodos para el tratamiento de resistencia a la insulina. | |
| BR112019008516A2 (pt) | derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo | |
| BR112018009413A2 (pt) | formulação oral sólida e método para preparar a formulação oral sólida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |